Not currently recruiting at UCLA
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Biohaven Therapeutics Ltd.
- ID
- NCT06132893
- Phase
- Phase 2/3 Epilepsy Research Study
- Study Type
- Interventional
- Participants
- Expecting 390 study participants
- Last Updated